INTRODUCTION:

Alzheimer's disease (AD) is pathologically characterized by an insoluble accumulation of amyloid-beta (Ab) protein in extracellular senileplaques blocking the neuronal synaptic junction and intracellular tangles that disrupt the transport system leading to malfunctions in biochemical communications between neurones .microtubule-associated protein (MAP) tau in intracellular neurofibrillary tangles (NFTs) are related to synaptic dysfunction and neuronal death¹ AD has had a significant impact on the global economy, costing $ 800

billion by 2015. These costs are expected to increase year on year, as the number of AD cases is expected to increase from ~ 50 million. Currently discover 82 million to 2030, and 152 million discover by 2050 year.²

Transmission therapies (DMTs) and symptomatic treatment are the classified categories of clinical trial of AD³. In clinical research gantenerumab, solanezumab was introduced to the patients. Dominantly Inherited Alzheimer’s Disease (DIAD) is predictable biological conversion of symptoms. 52 patients carrying a mutation with gantenerumab, 52 patients with solanezumab and 40 with placebo control. Gantenerumab reduced amyloid plaques, CSF (Cerebro Spinal Fluid) total tau significantly and can increase neurofibrillary tangles.⁴ Immediately Aducanumab got approval for the management of AD from the U.S. Food and Drug Administration (FDA). This is the earliest treatment approved by the FDA to address the basic biology of Alzheimer's disease. It shows the first treatment of amyloid release. This could be so beneficial for people to live their daily life, independence and grip memories for longer⁵

PATHOPHYSIOLOGY:

In hippocampus, amygdala, cortical areas of parietal, temporal frontal cortices neuronal loss are seen, but also subcortical nuclei such as serotonergic dorsal raphe, noradrenergic locus coeruleus, and cholinergic basal. The placing of the thighs follows a distinct pattern, from the trans-entorhinal cortex; as a result, the entorhinal cortex, the CA1 region of hippocampus and then cortical junction, where the lobes are most affected. The size and structure of the pipeline structure fits well with the severity of dementia, especially with the numbers of amyloid plaques.⁶

Tau protein enlargement is closely related to dementia and brain atrophy, including hippocampal atrophy. In Alzheimer's neuropathology the superfrontal cortex suffer from atrophy and loss of neurones, which occurs inflammation and deposition of amyloid plaques and bundles of connective tissue and abnormal set of protein fragments and due to this increase the occurrence of monocyte, macrophages in cerebral cortex and also uses microglial cells in parenchyma⁷

Tau protein and amyloid β hypothesis:

AD disease caused by is the formation of senile plaque, which is source by the amyloid-beta (Aβ). Typically, Aβs are small soluble peptides, produced by the amyloid precursor protein (APP) by the action of α, β and γ-secretase. The imbalance between β-amyloid (Aβ) production and approval leads to different types of toxic oligomeric,⁸ namely plaques, protofibrils and fibrils depending on the degree of oligomerization. The cause of Aβ formation is not yet clear, but the sequence, concentration and stability conditions of Aβ are important. The pathophysiology of Alzheimer's disease is identified in a number of areas such as cholinergic dysfunction, tau aggregation, and mitochondrial dysfunctions.⁹

Oxidative stress hypothesis:

Reactive oxygen species and reactive nitrogen species are produced in many common and unusual human processes, playing a versatile role as having beneficial functions in cellular signalling processes and toxic processes that can cause damage to cellular structures. High oxygen consumption in the brain, which consumes 20% more oxygen than the other mitochondrial respirative tissues, means that the brain is more susceptible to oxidative stress. A neuron is unit of the brain function, which contains an excess amount of polyunsaturated (fatty) acids. It can react with ROS, which can deals with lipid peroxidation response and cell apoptosis, in addition, low glutathione to neurons and is major causes of oxidative stress injure.⁸

Metal ion hypothesis:

Metal dyshomeostasis is part of the pathogenesis and progression of the diseases, including neurovegetative function and cancer. Chelators (metal) and Ionosphere are known as modulators of changed metal homeostasis,³⁶ and in clinical trials they are mostly used. Metal binding chemicals are not the only drugs that can detect metal conversion in homeostasis. especially copper, iron and other trace elements. Their percentages in brain are higher in AD.¹⁰

Cholinergic hypothesis:

The characterization of apo-lipo-protein E (APOE) genotype on the beneficial effect of acetyl-cholinesterase inhibitors (AChEIs) with the patients of Alzheimer's disease. AchEI medications are vital to the management of AD, and the APOE genotype is the most significant aspect related with AD. Lack of a major APOE effect is analysed in relation to AD's "Cholinergic Hypothesis", which began in 1976, recognizing that cholinergic neurons are not the primary goal of AD. Binding of Cholinergic receptor decreases in certain regions of the brain with mild to moderate AD and is associated with neuropsychiatric symptoms. Among strong aged adults, change of brain changed with age related to binding of cholinergic neurone. And this seems like it provide effective target of treatment Cholinesterase inhibitors (ChEIs) and donepezil had been used as a beginning for the treatment of AD for more than 20 years¹¹. The discovery that mutation associated with microtubule protein-tau (MAPT) caused fronto-temporal dementia and chromosome-related Parkinsonism (FTLD-17) was the discovery in the field, and provided genetic evidence to suggest good tau is sufficient to initiate neurodegeneration, in the absence of Aß. Therefore, developing vaccines against tau offers an additional benefit not only of benefit to AD, but also to a large segment of tauopathies.¹²

ANIMAL MODELS:

INVITRO MODELS:

Neurovascular and blood Brain barrier model: Neuron-glial interaction with the aforementioned problems associated with the difficulties in perfusing potential vascular bed, many other groups have focused specifically on the vasculature and in particular the BBB. Historically, BBB models used static systems where EC are cultured alone or with astrocytes and/or pericytes on a semipermeable membrane separating an upper and a lower chamber (e.g. of luminal flow as well as the 2D structure do not recapitulate the complex architecture of the BBB¹³ and therefore limit the cells sense and respond to the dimensionality and rigidity of their environment, and such qualities cannot be modelled spheroid systems consisting of human primary brain EC, primary pericytes and primary astrocytes spontaneously self-organize into a multicellular BBB-like structure with the glial cells in the middle and EC on the surface;¹⁴

In particular, Cho and colleagues generated BBB organoids expressing tight junctions, organoids are amenable for drug penetration studies using However, these structures do not allow specific manipulations of the BBB to enable real-time monitoring of barrier integrity in drug delivery studies, nor are these models perfusable through a physical lumen. the EC permeability is 2 × 10–5 cm/s using 10 kDA dextran and neuron have neurite outgrowth and activity upon KCl stimulation using the calcium dye X-Rhod-1, this study mixed species reducing the relevance of the model, Adriani et Human neurons were integrated in a sandwich microfluidic device where primary brain microvascular EC line a microfluidic channel with a polycarbonate filter membrane with 0.2μm pores separating the brain chamber composed of primary astrocytes and pericytes and iPSC derived neurons cultured in collagen-I.¹⁵

Recently Maoz and colleagues developed a linked organ-on-chip NVU system consisting of a BBB chip (primary human brain EC, pericytes and astrocytes) linked via cerebrospinal fluid perfusion (0.0007dyne/cm2, 0.06 mL/h) to a brain chip composed of hippocampal stem cell derived neurons and primary astrocytes. Under luminal flow conditions (0.02dyne/cm2, 0.06 mL/h), the BBB was impermeable to both BSA (66.5 kDa) and coupling between BBB and the neurons, this model lacks anatomical fidelity as the BBB and neurons are separated in different chips with EC and astrocytes/pericytes further separated by a porous (0.4μm) polyethylene terephthalate microfluidic device where iPSC-derived EC were cultured in a perfusable channel with a polydimethylsiloxane porous membrane (7μm pores) separating the brain chamber composed of iPSC-derived neurons and astrocytes (Vatine The authors demonstrated BBB function using both luminal circulated 3 kDa FITC-dextran (0.03mL/h), the porous membrane. In this sandwich model, the TEER corresponding to the lower limit of reported in vivo BBB using the cell permeable calcium dye Fluo-4 and confocal microscopy.¹⁶ The authors showed that neurons in the chip sodium channel blocker tetrodotoxin indicating that the chip environment supports neuronal synaptogenesis and Further, this model allows the use of patient derived iPSCs and the possibility to flow patient blood through the circulation channel opening avenues to study Due to the nature of microfluidic chip production using soft lithography, perfusion channels are rectangular resulting in a circular channel, several groups have used micro-needles placed into a collagen gel. needle is removed to generate a hollow channel that is groups have used viscous fingering to create a hollow channel in a collagen-I matrix containing glial cells and pericytes a single circular vascular channel, there is as yet no study demonstrating the ability to culture functional human neurons in these systems. generated a fully humanized model using a parallel chip design where iPSC-derived EC formed a perfusable vascular network in a porcine skin collagen-I matrix containing Ipsc derived neurons.^17,18

Parenchyma model”

in vitro translation tools to enhance our understanding of the biology of the brain the benefit of glial coculture for neuronal maturity and activity In order to recapitulate the more complex cellular interactions found in the brain, 3D cultures of brain cells have been developed to more closely model the architecture of the brain and are called organoids or spheroids.¹⁹ In the presence of semi-minima, brain organoids mimic the tissue architecture and physiological functions of the developing human brain 3D cultures of the cortical forebrain and the incorporation of neural spheroids into the developing brains, these organoids exhibit a specific regional increase of dorsal cortical morphology, choroid plexus, and ventral forebrain identity. An additional specification occurs in the dorsal cortical areas AUTS2+ cells which mark the areas of the prefrontal cortex and TSHZ2 + cells which mark the occipital lobe. Functional cortical neurons develop within brain organoids capable of spontaneous calcium peaks brain organoids grow stochastically, giving rise to a range of types of neuronal cells, including the dorsal and ventral forebrain, midbrain, hindbrain and retina;²⁰ The stochastic nature of brain organoid formation can produce cell compositions varying between batches, lines and protocols. This cell heterogeneity in brain organoids can be limited by changing the composition of the medium to drive cells to a fate. dorsal forebrain identity and the additional addition of ventral forebrain organoids. dopaminergic organoids are generated with a double SMAD inhibition and tyrosine hydroxylase positive develop in dopaminergic neurons. An advantage of 3D brain organoids for in vitro modelling oligodendrocyte precursor cells, were observed in organoids.²¹ Transcriptional analyses of astrocytes isolated from the brain organoids show the transition of astrocytes from a fatal state to a more mature state immature neurons of human cerebral cortical spheroids. times, developing the ability to interact with neurons and myelinated neuronal axons.²²

Cerebrovascular model:

One approach to vascularizing brain organoids is to transplant organoids into animal models.²³ Developed an in vivo model in which human brain organoids from human embryonic stem cells (hESC) were transplanted into the brains of immunodeficient NODSCID mice. grafts developed a vascular system through which host blood flows and had reduced apoptosis. post-transplant organoids showed progressive neuronal differentiation patterns and brain organoids can not only remove the necrotic core but also aid in the development of a mature system. Similarly, implanted brain organoids coated with EC mice and observed increased organoid vascularization. of these models the blood vessels are of partial murine²⁴. In vitro 3D cerebral organoid models is thru codifferentiation of global organization with neural cell types. hESC self-aggregated neural organoids with VEGF, increased vascularisation is discovered with cells expressing CD31 and the BBB tight junction marker claudin-5 while not a big reduction in neural markers. differentiation, promoted tube-like structures enclosed by α-smooth muscle simple protein positive pericyte-like cells by four months once 20% of the cells express ETV2, within the presence of dox a fancy tube network is shaped in the cerebral organoids. evoked global organization incontestable enlarged expression of the tight junction proteins zonule occludens-1, claudin-5 and occluding, increased expression of the nutrient transporters aldohexose Another approach to vascularize 3D organoids in vitro is to coculture cerebral and global organization spheroids.²⁵ Generated hybrid NVU spheroids by combining neural root cell spheroids mesenchymal stem cells. culture shows markers of MAP2+ neurons, GFAP+ astrocytes and CD31+ EC in addition as enlarged expression of the BBB resistant protein, and tight junction marker occludens-1. Moreover, these vascularized organoids expressed bigger Recently, generated tubeized organoids by co-culture of human vena global organization with BBB epithelium phenotypes with enlarged expression of Furthermore, vascular organoids display bigger chemical and electrical junction Increasing complexness of the 3D culture systems by the inclusion of tube, neural and neuroglia cell varieties brings vascular and neuronal physiology among the system, if vascularized brain organoids are ready to be perfused, core in organoids however additionally allow the insertion of blood cells, organoid are their variability, but this might be extended^25,26.

Models about neurovascular signals:

The use of in vitro models to review in vivo physiology and not every model is suited to answer each biological question, biological and engineering components of recent models as we progress towards an ideal NVU model.²⁷ Increased cellular quality in future models will enhance systems, inclusion of tube-shaped structure and parenchymal cell types models, vessels intentional of international organisation have to be compelled to be compelled to be structurally supported by applicable mural cells, similar to pericytes in the capillary²⁸ and SMC in larger vessels, that regulate world organisation to mural cells, astrocytes got to kind end feet structures to act with the vessels as they regulate lumen dilation and of EC, mural cells and astrocytes is provided collectively by BM proteins albuminoid IV, laminin, nidogen and perlecan. BM protein composition, systems incorporating relevant BM are progressing to be ready to investigate mechanisms of these illness connected changes.

There are few model for understanding the process like deposition of amyloid plaques and accumulation of tau can be formed by Cortical model with 3D hydrogel , CAA and amyloid plaques accumulation are seen at NVU models based on tissue enjeering and microfluidic chip.²⁹

SH-SY5Y Cell model:

Many areas of the neurosciences hampered by the lack of relevant in vitro models that resemble nearly mature neurons to categorical human proteins.³⁰ This is often very true in the analysis of Alzheimer's disease (AD) where the cell models normally used do not include axons, synapses and human proteins, all involved in the pathology. Human and adult living neurons for functional and interventional studies are not readily available, so completely different immortalized cell lines are used as an alternative. However, these cell lines, along with the frequently used metastatic tumor cell line SHSY5Y, lacking many options that delineate somatic cells, as well as neural morphology, suppression of cell division, and the expression of markers. neurospecificity.³¹ A variety of proteins is used as a marker for mature neurons, comparable to neuron-specific βIII tubulin, which is almost exclusively expressed in neurons and may be a marker for differentiation and impaired proliferation. A Sinapsi pen is conitationSV2 protein bag, a conjugated protein gift in neurones premium vesicles and endocrine cells, in question in the conjugation structure and the release of the emitter. Fumimorthermore, nuclear nuclear Marker Neun also more and more and more and more likewise, as conjugation and failure events, there is an excellent need for suitable human cell models to learn these events here as well as in various fields of neuroscience. In the donation study, we present a technique for differentiating a readily available human metastatic tumor cell line into cells showing high similarity to adult human neurons. Thus providing a reproducible, readily available and inexpensive technique with qualities which modify the studies of cellular structures and events of great importance in neuroscience.³²

One of the main characteristic options of neurons is their long processes with an intensive transport system and also interaction with alternative neurons via synapses. Lately various studies in the AD field have focused on tubule transport because it tends to look like targeting and junction deficit. The model offers the possibility of examining these events, as it shows the transport of cysts on long neurites imaging the victimization period of living and morphologically differentiated cells at ECM gel intervals. In addition, these well-differentiated cells showed obvious synaptic structures and intense staining of the synaptic vesicle supermolecule Sv2, required for every junction structure and neurochemical release, was present at the sites of neurotic contacts. This information provides evidence for the appearance of synapses in differentiated cells although the definitive evidence for practical synapses would be electrophysiological and experimental. Unfortunately, due to the character of the ECM gel, the patch clamp experiments were technically difficult to perform. other studies on the practicality of these synapses would be interesting.^33,34

The version indicates that SH-SY5Y malignant tumour cells are also differentiated into neuron-like cells showing morphological and biochemical functions of mature neurons. Furthermore, those cells show nerve fibre expression of mature letter of the alphabet supermolecule isoforms. Taking all parts into attention scientists placed the good overall vegetative cell differentiation become disbursed the usage of RA pre-treated SH-SY5Y cells attended with the help of victimization EW gel culturing with addition of BDNF, NRG, NGF, and VitD3 to the medium. This mobile in vitro version has the potential to the neuro science research.³⁵

3D brain tissue culture model

3d culture of neuronal cell is apt for generating of extracellular build-up of Aβ. They are capable of reiterate invivo brain condition and can form neuronal network like structure.³⁶ 3D culture vigorously spread their neuronal discrimination 4R (adult tau isoform) compared to 2D model, which is mostly require in NFT pathology and tau accumulation³⁷.

3D culture model is also advantageous for reiterate of tau neuropathy without FTD transmutation. And study shows that filament like structure of insoluble tau fibre protein ³⁸. In future it can be shown the neuronic cell damage process by 3D neurone culture.

In another aspect 3D cell culture are used for new drug telecast procedure. The pipe line drug can be developed. This culture model is cheap and work very fast. Basically, 3D culture models are initiative system to ensure the efficacy of new drug therapy.

Most stirring use of 3D culture is HTS (High Throughput Screening). It offered rapid testing of much compounds in early time. 3D culture model of Matrigel can easily manage the HTS format³⁸.

3D models are used to save time by reducing mice model tests. And it is also beneficiary for doing cross check of AD drug by 3D HTS³⁹. Another models are like c.Elegans, Drophila, Zebrafish, knock in mouse model.

INVIVO MODELS:

Transgenic mice expressing human app and psen1 with fad mutation

The first discovered model was PDAPP mouse, which shows Indiana mutation (APP^V717F) with human APP drawn with PDGF –β. Which gives striking overview about human APP⁴⁰. The mutated mice models Tg2576 were closely tracked. This AD model drawn the significant experimental effect on human APP⁴¹. Tg2576 mice extend plaque in hippocampus, cortex and cerebellum part and memory destruction also shown⁴². APP23 mice have significant rolemin formation of plaques and localized neurodegeneration compared to Tg2576 mice model⁴³. It can discover that APP and promoter can manipulate the time coarse related with transgenic mice model. Numerous FAD coupled mutation are developed in mutated mice,j20 model of mice express Indiana mutation and Swedish⁴². Promoter PS1^L166P and APP^K670N/M671L grades plaque formation incredibly early like 6 weeks, while expression of PS1^M146Land APP^K670N/M671L outcome roughly after 6 month⁴⁴. The APP/PS1 mice model that has broadly experimented is 5xF AD model; these mice convey the London (APP^V717I ), Swedish (APP^K670N/M671L) and Florida (APP^I716V) APP and PS1^L286V mutations and PS1^M146L.⁴⁵ so there is minor neurodegeneration is developed in mouse model of very aged animal model. but none of models urbanized neurofibrillary tangles⁴⁶.

Transgenic mice model with tau and tangles:

A less number of laboratory animal model experiments are done with both displays tangles and plaques.^47,48 Continuous experiment on both tangles amd plaques has examined as it got very difficult. Plaques and Tangles are only seen in older age on the animal model. No mice model could not it earlier. Only 3xTg mouse can show early development of plaque. In 3-4 month this 3xTg mouse developed it’s intraneuronal amyloid beta and developed plaques in 6 month to hippocampus and cortex area⁴⁹.

Although this model mice cannot show tau and mutated Aβ as compared to sAD. Moreover, huge amount of spreading of Tangles and Plaques are not observed until models get old age. Even the pathophysiology is less similar able compared to the AD.

Transgenic rat model:

A few experiments are done with transgenic rat models. Transgenic rat are most appropriate animal model than transgenic mice model. There genetic features, morphology and pathological interaction are more similar with humans. Their large brain can store CSF. Transgenic rat’s brain can image anything easily. That’s why complex experiments can be done with this rats⁵⁰. There are few rat model like TgF344 rat, give well reprenation of AD⁵¹.

All models give excellent outcome about amyloid plaque. The TgF344 Rats developed age dependent aggregation of amyloid beta which shows tau pathy. Culturing Aβ in TgF344 Rat is much satisfying than PSAPP mice, whether cultured the same human transgenes. This AD Rat model shows that NFT pathology are free from tau mutation of human. Although Tg rat can explore the full pathology of human AD. This new model definitely represent a neuroscience about AD research⁵². McGill-R-Thy1-APP homozygous animal can show a degree of cognitive damage by age⁵³. So can say, transgenic Rat are more advantageous than transgenic mice.

Unique transgenic mouse model for AD:

A many transgenic mouse models experiments has initiated for replications the pathological characterisation of AD. Transgenic mouse model Tg-SwDI is a very good model for CAA⁵⁴. This model can express Duch, Lowa, Swedish mutation⁵⁵. Build-up of Aβ in vesicles is visible in SwDI mice model but plaques in parenchyma in not properly developed, started at the age of 3 year⁵⁴. The ongoing clinical trials approaches to diminish amyloid deposition, without getting complication. The joint experiments shows a major problem like Vasoenema, ARIA-E are formed⁵⁶.

ARIA is a major problem discovered after Aducanumab trial 35% people expired after forming this ARIA⁵⁷. The APP E693Δ-Tg model express APPE^{693Δ mutation,}result is from 8 month cognitive impairment, Aβ oligomer, synaptic impairment increases. Whether plaques and tau aggregation does not show⁵⁸. Advantage of this models it can replicate specific pathological character of AD models. But disadvantages are they can’t replicate them selt as a complete models of AD.

New therapies:

A test indicated that probiotic intake may improve psychological feature operate Associate in Nursing mood in community-dwelling old individuals⁵⁹. Metallic element oligomannate (GV-971) is an orally given mixture imitative from marine brown algae. A study according that GV-971 could rework the gut microbiota by decreasing the concentrations of essential amino acid and essential amino acid in the faecal matter and blood and reducing T helper 1-related neuroinflammation within the brain⁶⁰. In addition, GV-971 willsimply penetrate the blood–brain barrier to directly bind to Aβ and inhibit Aβ fibre formation.

Anti-inflammatory drug therapy:

Neuroinflammation is taken into account a vital pathological mechanism that contributes to the pathological process of AD. Chronic activation of the systemends up inthe discharge of unhealthy cytokines Associate in Nursing d venomous factors⁶¹. Thus, anti-inflammatory medicine might also be value considering as potential anti-AD therapeutics. A meta-analysis showed that the employment of nonsteroidal anti-inflammatory drug drugs (NSAIDs) was considerably related to a reduced risk of AD in empirical studies; however, in an exceedingly single randomised controlled trial, NSAIDs showed no important impact on AD risk ⁶². Minocycline, an anti-inflammatory tetracycline, was ready toshield against the venomous effects of Aβ in vitro and in an exceedinglynimal models of AD however didn't delay the progress of psychological feature or purposeful impairment in AD patients in a clinical test.

Lipid metabolism parameter:

Changes in macromolecule metabolism, apolipoproteins, and leptin are related with AD. The apolipoprotein ɛ4 isoform variant may be a major genetic risk issue for late-onset AD. animal oil wealthy in ω-3 long-chain unsaturated fatty acids is believed to be useful for psychological feature function⁶³. A study of 1293 older subjects with high vessel risk found that multidomain intervention combined with polyunsaturated fatty acids would possibly improve orientation and long-term memory. However, a 3-year multicentre trial of 1680 participants showed that polyunsaturated fatty acids had no vital effects on cognitive decline⁶⁴. Statins are a gaggle of medication ordinarily wont to lower cholesterin levels within the blood. A diagnosis study found that statins were able to scale back Aβ levels in yeast, and metanalyses reportable that statins would possibly reduce dementedness risk and have useful effects on Mini-Mental State Examination scores in AD patients. However, alternative studies and meta-analyses silent that there was meagrely proof supporting the effectivity of statins in treating AD or lowering AD risk ^65,66.

σ-1 receptor agonists therapy:

σ-1 receptor agonists initiation of σ-1 receptor has been shown to own neuroprotective effects and will scale back key pathophysiological processes in AD, together with hyperphosphorylation of letter of the alphabet Associate in Nursing d aerobic stress. Blarcamesine (ANAVEX2-73), a selective σ-1 receptor agonist, was reported to exhibit smart safety and tolerability in patients with mild-to-moderate AD during apart IIa clinical study⁶⁷. Part IIb/III clinical studies are ongoing. AVP-786 could be a compound consisting of a mix of deuterated (d6)-dextromethorphan and an ultra low dose of quinidine; in vitro and in animal models, this drug was reported to be a σ-1 receptor agonist, a monoamine neurotransmitterre-uptake Associate in Nursing d saltunharness inhibitor, and NMDA receptor antagonist⁶⁸. It'scurrently in clinical trials for the treatment of agitation in patients.

Natural product therapy:

The ginkgo extract EGb 761 is wide employed in the treatment of medicine disorders, as well as AD. Studies showed that EGb 761 might considerably improve psychological feature function, medical specialty symptoms, and activities of daily alive patients with gentleto- moderate dementedness and relieve symptoms with moderate cognitive impairment (MCI). gymnospermous treelide A, another compound has been extracted from Ginkgo biloba, was found to calm Aβ-induced irregular depolarisation and block NMDA receptors⁶⁹.

Down regulation of glycogen synthase kinase-3β (GSK-3β) and CDK5 are reported by Curcumin having anti-inflammatory character and can permeate BBB. Dietary supplement with curcumin can reduce the stage of GSK-3β, can reduce risk of type 2 diabetes mellitus and AD⁷⁰.

Coconut oil is resource of ketone body. Dietary supplement riched with coconut oil seems to recover cognitive behaviour of AD and it is validate by gender⁷¹.

AducanumabGantenerumab and Solanezumab:

Aducanumab infusions doses are done monthly. it takes c1 hr to complete its infusion dose. 1mg/kg and 3mg/kg are given frequently by 1st, 2nd dose and 3rd, 4th dose.6mg/kg given in 5th and 6th dose of infusion. Further infusions are done away from 1 month with 10 mg/kg dose. So, it’s seeming that higher dose are worked in AD patients but lower dose causes AREA. ARIA can successfully cured in most of the patients who engaged themselves in important tests without stopping the treatment; ARIA leads to discontinuation of trials at 0.6% of patients on placebo and 6.2% of patients on aducanumab⁷².

The patients with mutation of AD are treated with gantenerumab, solanezumab. 52 patients with solanezumab, gantenerumab and 40 with placebo were assign. Both drug targets their Aβ compared to controls. Amyloid plaques were removed by Gantenerumab and solanezumab did not show good effect on downstream biomarker. In DIAD patients this drug did not show cognitive decline. A symptomatic patient refuses before getting the desired targeted dose 4.

CONCLUSION:

In this review we can say that the current progress of new therapeutics like lipid metabolism, inflammation, and disease customize genes to AD in preclinical and clinical research. It’seeming that higher dose are worked in AD patients but lower dose causes AREA. ARIA can successfully cured in most of the patients who engaged themselves in important tests without stopping the treatment.

REFERENCE:

1. Maryam Heydari, Farideh Razban, Tayebeh Mirzaei, Shahin Heidari. The Effect of Problem Oriented Coping Strategies Training on Quality of Life of Family Caregivers of Elderly with Alzheimer. Asian J. Nur. Edu. and Research.2017; 7(2): 168-172.

2. Dhanya George, Anu Jacob Kachappillil. The level of Memory Impairment among elderly in a rural community of Ernakulam District. Asian J. Nursing Education and Research. 2020; 10(1): 107-109.

3. Jismi Jigu, Jitty Jose, Leema Thomas, Shinu Sherry, Vincy Varghese, Sheeja S. A Study to Assess the Knowledge regarding Alzheimer's Disease among people above 45 years of age in selected areas at kollam. Asian Journal of Nursing Education and Research. 2022; 12(2):224-6.

4. Rahul P. Jadhav, Manohar D. Kengar, Omkar V. Narule, Vikranti W. Koli, Suraj B. Kumbhar. A Review on Alzheimer’s Disease (AD) and its Herbal Treatment of Alzheimer’s Disease. Asian J. Res. Pharm. Sci2019; 9(2):112-122.

5. P Vijayalakshmi, R Radha. In vitro Anti-Alzheimer and Anti-Oxidant activity of the Peels of Citrus maxima fruits. Journal of Pharmacology and Pharmacodynamics. 2016; 8(1): January -March, 17-22

6. Sampoornam.W, Basil V. Kuriakose. Effectiveness of Visual Images Mnemonic Training on Memory among Alzheimer’s Disease Patients at Alzheimer’s and related Disorders society of India, Cochin, Kerala. Int. J. of Advances in Nur. Management. 2019; 7(2):95-96

7. Patel Minesh. A Review on Importance of Artificial Intelligence in Alzheimer’s Disease and it’s Future Outcomes for Alzheimer’s Disease. Research Journal of Pharmacology and Pharmacodynamics.2022; 14(1):13-2.

8. Vasudev Pai, Chandrashekar K. S, C. S. Shreedhara, Aravinda Pai. In-Silico and In-Vitro correlation studies of natural β-secretase inhibitor: An approach towards Alzheimer’s Disease. Research J. Pharm. and Tech 2017; 10(10):3506-3510.

9. Chandni Naidu, Dhanush Kumar, N Maheswari, M Sivagami. Prediction of Alzheimer’s Disease using Brain Images. Research J. Pharm. and Tech 2018; 11(12): 5365-5368.

10. Dhinakaran S, Tamilanban T, Chitra V. Targets for Alzheimer’s Disease. Research J. Pharm. and Tech. 2019; 12(6):3073-3077.

11. Rahul P. Pol, N. S. Naikwade, R. J. Dias. Targeting Aβ protein in Alzheimer’s Disease. Research J. Pharm. and Tech 2020; 13(2):1004-1008.

12. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer’s disease. Biochim Biophys Acta - Mol Basis Dis. 2005; 1739(2):216–23.

13. Qi S, Dong J, Xu Z, Cheng X, Zhang W. PROTAC : An Effective Targeted Protein Degradation Strategy for Cancer Therapy. 2021; 12(May):1–13.

14. Schwestermann T, Eglinton TI, Haghipour N, Mcnichol AP, Ikehara K, Strasser M. Event-dominated transport, provenance, and burial of organic carbon in the Japan Trench. Earth Planet Sci Lett [Internet]. 2021; 563:116870. Available from: https://doi.org/10.1016/j.epsl.2021.116870

15. Brown CR, Eskin JA, Hamperl S, Griesenbeck J, Jurica MS, Boeger H. Chapter 9 Chromatin Structure Analysis of Single Gene Molecules by Psoralen Cross-Linking and Electron Microscopy. 1228:93–121.

16. Wolff T, Iyer NA, Rubin GM. Neuroarchitecture and Neuroanatomy of the Drosophila Central Complex : A GAL4-Based Dissection of Protocerebral Bridge Neurons and Circuits. 2015; 1037:997–1037.

17. Bang S, Lee S, Ko J, Son K, Tahk D. A Low Permeability Microfluidic Blood-Brain Barrier Platform with Direct Contact between Perfusable Vascular Network and Astrocytes. Sci Rep [Internet]. 2017; (December 2016):1–10. Available from: http://dx.doi.org/10.1038/s41598-017-07416-0

18. Lee S, Mogle JA, Jackson CL, Buxton OM. What ’ s not fair about work keeps me up : Perceived unfairness about work impairs sleep through negative work-to-family spillover. Soc Sci Res [Internet]. 2019; 81(March 2018):23–31. Available from: https://doi.org/10.1016/j.ssresearch.2019.03.002

19. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. 2006; 2(3):663–76.

20. Lancaster MA, Renner M, Martin C, Wenzel D, Bicknell S, Hurles ME, et al. Europe PMC Funders Group Cerebral organoids model human brain development and microcephaly. 2014; 501(7467).

21. Madhavan M, Nevin ZS, Shick HE, Garrison E, Karl M, Clayton BLL, et al. HHS Public Access. 2019; 15(9):700–6.

22. Ormel PR, Sá RV De, Bodegraven EJ Van, Karst H, Harschnitz O, Sneeboer MAM, et al. Microglia innately develop within cerebral organoids. Nat Commun [Internet]. 2018; Available from: http://dx.doi.org/10.1038/s41467-018-06684-2

23. Shou Y, Liang F, Xu S, Li X. The Application of Brain Organoids : From Neuronal Development to Neurological Diseases. 2020; 8(October):1–10.

24. Ham DJ, Börsch A, Lin S, Thürkauf M, Weihrauch M, Reinhard JR, et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nat Commun [Internet]. (2020). Available from: http://dx.doi.org/10.1038/s41467-020-18140-1

25. Song L, Chen Y, Guo Q, Huang S, Guo X, Xiao D. Regulating the Golgi apparatus sorting of proteinase A to decrease its excretion in Saccharomyces cerevisiae. J Ind Microbiol Biotechnol [Internet]. 2019; 46(5):601–12. Available from: https://doi.org/10.1007/s10295-019-02147-9

26. Article V, Baufeld A, Vanselow J. A Tissue Culture Model of Estrogen-producing Primary Bovine Granulosa Cells. 2018; (September):1–7.

27. Thomsen J, Ramesh K, Sanders T, Bleich M, Melzner F. Calcification in a marginal sea – influence of seawater [ Ca 2 + ] and carbonate chemistry on bivalve shell formation. 2018; 1469–82.

28. Outcomes M. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. 2020;

29. Schaffhauser A, Payette S, Garneau M, Robert C. Soil paludification and Sphagnum bog initiation : the influence of indurated podzolic soil and fire. 2016;

30. Katsetos CD, Herman MM, Mo SJ. Class III ␤ -Tubulin in Human Development and Cancer. 2003; 96(February):77–96.

31. Sarnat HB, Nochlin D, Born DE. Neuronal nuclear antigen ( NeuN ): a marker of neuronal maturation in the early human fetal nervous system 1. 1998; 20(3):88–94.

32. 81.pdf.

33. Vos KJ De, Grierson AJ, Ackerley S, Miller CCJ. Role of Axonal Transport in Neurodegenerative Diseases ∗. 2008;

34. Nimmrich V, Ebert U. Is Alzheimer ’ s Disease a Result of Presynaptic Failure ? Synaptic Dysfunctions Induced by Oligomeric ß-Amyloid. 2009; 12:1–12.

35. Zheng L, Roberg K, Jerhammar F, Marcusson J, Terman A. Autophagy of amyloid beta-protein in differentiated neuroblastoma cells exposed to oxidative stress. 2006; 394:184–9.

36. Tang-Schomer MD, White JD, Tien LW, Schmitt LI, Valentin TM, Graziano DJ, et al. Bioengineered functional brain-like cortical tissue. Proc Natl Acad Sci U S A. 2014; 111(38):13811–6.

37. D’Souza I, Schellenberg GD. Regulation of tau isoform expression and dementia. Biochim Biophys Acta - Mol Basis Dis. 2005; 1739(2):104–15.

38. Kim YH, Choi SH, Avanzo CD, Hebisch M, Bylykbashi E, Washicosky KJ, et al. disease. 2016; 10(7):985–1006.

39. Raja WK, Mungenast AE, Lin YT, Ko T, Abdurrob F, Seo J, et al. Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer’s disease phenotypes. PLoS One. 2016; 11(9):1–18.

40. Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Vol. 373, Nature. 1995. p. 523–7.

41. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Amyloid Plaques in Transgenic Mice. Science (80- ). 1996; 274(October):99–102.

42. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997; 94(24):13287–92.

43. Sturchler-Pierrat C, Staufenbiel M. Pathogenic mechanisms of Alzheimer’s disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci. 2000; 920:134–9.

44. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006; 7(9):940–6.

45. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J Neurosci. 2006; 26(40):10129–40.

46. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, et al. A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010; 30(14):4845–56.

47. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, et al. Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice. Neurobiol Dis [Internet]. 2010; 37(2):294–306. Available from: http://dx.doi.org/10.1016/j.nbd.2009.09.004

48. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (80- ). 2001; 293(5534):1487–91.

49. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging. 2003; 24(8):1063–70.

50. Do Carmo S, Cuello AC. Modeling Alzheimer’s disease in transgenic rats. Mol Neurodegener [Internet]. 2013; 8(1):1. Available from: Molecular Neurodegeneration

51. Pan D, Zeng A, Jia L, Huang Y, Frizzell T, Song X. Early Detection of Alzheimer’s Disease Using Magnetic Resonance Imaging: A Novel Approach Combining Convolutional Neural Networks and Ensemble Learning. Front Neurosci. 2020; 14(May):1–19.

52. Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, et al. A transgenic alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Aβ, and frank neuronal loss. J Neurosci. 2013; 33(15):6245–56.

53. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, Dewilde A, et al. A novel transgenic rat model with a full alzheimer’s - Like amyloid pathology displays pre - Plaque intracellular amyloid -β- Associated cognitive impairment. J Alzheimer’s Dis. 2010; 20(1):113–26.

54. Davis J, Xu F, Deane R, Romanov G, Previti M Lou, Zeigler K, et al. Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor. J Biol Chem. 2004; 279(19):20296–306.

55. Kamp JA, Moursel LG, Haan J, Terwindt GM, Lesnik Oberstein SAMJ, Van Duinen SG, et al. Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Rev Neurosci. 2014; 25(5):641–51.

56. Justyna W. 乳鼠心肌提取 {HHS} {Public} {Access}. Physiol Behav. 2017; 176(5):139–48.

57. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature [Internet]. 2016; 537(7618):50–6. Available from: http://dx.doi.org/10.1038/nature19323

58. Forloni G, Balducci C. Alzheimer’s Disease, Oligomers, and Inflammation. J Alzheimer’s Dis. 2018; 62(3):1261–76.

59. Kim CS, Cha L, Sim M, Jung S, Chun WY, Baik HW, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community- dwelling older adults: A randomized, double-blind, placebo-controlled, multicenter trial. Journals Gerontol - Ser A Biol Sci Med Sci. 2021; 76(1):32–40.

60. Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res [Internet]. 2019; 29(10):787–803. Available from: http://dx.doi.org/10.1038/s41422-019-0216-x

61. Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimer’s Dement [Internet]. 2016; 12(6):719–32. Available from: http://dx.doi.org/10.1016/j.jalz.2016.02.010

62. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020; 9(1):1–12.

63. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Sao Paulo Med J. 2012; 130(6):419.

64. Rolland Y, Barreto P de S, Maltais M, Guyonnet S, Cantet C, Andrieu S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain lifestyle intervention on muscle strength in older adults: Secondary analysis of the multidomain alzheimer preventive trial (MAPT). Nutrients. 2019; 11(8).

65. Mcguinness B, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2014; 2014(7).

66. Dhakal S, Subhan M, Fraser JM, Gardiner K, Macreadie I. Simvastatin Efficiently Reduces Levels of Alzheimer’s Amyloid Beta in Yeast. Int J Mol Sci. 2019; 20(14):1–12.

67. Hampel H, Williams C, Etcheto A, Goodsaid F, Parmentier F, Sallantin J, et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimer’s Dement Transl Res Clin Interv. 2020; 6(1):1–15.

68. Marcinkowska M, Śniecikowska J, Fajkis N, Paśko P, Franczyk W, Kołaczkowski M. Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates. CNS Drugs [Internet]. 2020; 34(3):243–68. Available from: https://doi.org/10.1007/s40263-020-00707-7

69. Kandiah N, Ong PA, Yuda T, Ng LL, Mamun K, Merchant RA, et al. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®. CNS Neurosci Ther. 2019; 25(2):288–98.

70. Thota RN, Rosato JI, Dias CB, Burrows TL, Martins RN, Garg ML. Dietary supplementation with curcumin reduce circulating levels of glycogen synthase kinase-3Β and islet amyloid polypeptide in adults with high risk of type 2 diabetes and Alzheimer’s disease. Nutrients. 2020; 12(4).

71. Platero JL, Cuerda-Ballester M, Ibáñez V, Sancho D, Lopez-Rodríguez MM, Drehmer E, et al. The impact of coconut oil and epigallocatechin gallate on the levels of il-6, anxiety and disability in multiple sclerosis patients. Nutrients. 2020; 12(2):1–10.

72. Scheltens P, Vijverberg EGB. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimer’s Dis. 2021; 8(4):412–3.

Received on 21.12.2022 Modified on 05.06.2023

Asian J. Res. Pharm. Sci. 2024; 14(1):34-42.

DOI: 10.52711/2231-5659.2024.00006